ciprofloxacin has been researched along with Sclerosis, Systemic in 3 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Similar effects were observed in SSc-interstitial lung disease (ILD) lung fibroblasts." | 1.38 | Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1. ( Bujor, AM; Christmann, RB; Haines, P; Junie, M; Lafyatis, R; Padilla, C; Sampaio-Barros, PD; Trojanowska, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bujor, AM | 1 |
| Haines, P | 1 |
| Padilla, C | 1 |
| Christmann, RB | 1 |
| Junie, M | 1 |
| Sampaio-Barros, PD | 1 |
| Lafyatis, R | 1 |
| Trojanowska, M | 1 |
| Ozgocmen, S | 1 |
| Kaya, A | 1 |
| Coskun, BK | 1 |
| Over, KE | 1 |
| Bucknall, RC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind Randomized Clinical Trial to Evaluate the Reduction of Pain in the Wounds Treatment Previously Applying Lidocaine Topical Solution vs Placebo, in the Outpatients Area.[NCT03676556] | Phase 3 | 46 participants (Anticipated) | Interventional | 2021-06-16 | Recruiting | ||
| Randomised, Double-blind Clinical Trial to Evaluate the Reduction of Pain in the Wounds Treatment Previously Applying Lidocaine Topical Solution vs Placebo[NCT02584335] | Phase 4 | 7 participants (Actual) | Interventional | 2015-07-31 | Terminated (stopped due to Difficulties with the recruitment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for ciprofloxacin and Sclerosis, Systemic
| Article | Year |
|---|---|
Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1.
Topics: Cartilage Oligomeric Matrix Protein; Case-Control Studies; Cells, Cultured; Ciprofloxacin; Collagen | 2012 |
Topical lidocaine helps reduce pain of digital ulcers in systemic sclerosis (scleroderma).
Topics: Administration, Oral; Administration, Topical; Anesthetics, Local; Anti-Infective Agents; Ciprofloxa | 2006 |
Topical lidocaine helps reduce pain of digital ulcers in systemic sclerosis (scleroderma).
Topics: Administration, Oral; Administration, Topical; Anesthetics, Local; Anti-Infective Agents; Ciprofloxa | 2006 |
Topical lidocaine helps reduce pain of digital ulcers in systemic sclerosis (scleroderma).
Topics: Administration, Oral; Administration, Topical; Anesthetics, Local; Anti-Infective Agents; Ciprofloxa | 2006 |
Topical lidocaine helps reduce pain of digital ulcers in systemic sclerosis (scleroderma).
Topics: Administration, Oral; Administration, Topical; Anesthetics, Local; Anti-Infective Agents; Ciprofloxa | 2006 |
Regression of skin changes in a patient with systemic sclerosis following treatment for bacterial overgrowth with ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Diarrhea; Female; Humans; Middle Aged; Scleroderma, Systemic; | 1998 |